David Hyman
MD
Chief Medical Officer
👥Biography 个人简介
David Hyman pioneered basket trial methodology at Memorial Sloan Kettering and led the pivotal larotrectinib trials that resulted in the first tumor-agnostic FDA approval based on a molecular alteration. He has been a key figure in developing the regulatory and clinical framework for biomarker-selected, histology-independent drug approvals. His work spans TRK, RET, and other fusion oncoproteins.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 David Hyman 的研究动态
Follow David Hyman's research updates
留下邮箱，当我们发布与 David Hyman（Relay Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment